PDCD1 and neoplasm: Thus, it was only a question of time until first clinical trials combined IDO inhibitors like epacadostat or navoximod with inhibitors targeting the PD-1/PD-L1 axis or CTLA-4 in differnt tumor entities, including advanced melanoma (19, 63–66).